Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Cash & Equivalents (2018 - 2025)

Historic Cash & Equivalents for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to $1.4 million.

  • BioNexus Gene Lab's Cash & Equivalents fell 4908.39% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 4908.39%. This contributed to the annual value of $2.9 million for FY2024, which is 3609.67% down from last year.
  • Per BioNexus Gene Lab's latest filing, its Cash & Equivalents stood at $1.4 million for Q3 2025, which was down 4908.39% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, BioNexus Gene Lab's Cash & Equivalents registered a high of $6.1 million during Q3 2023, and its lowest value of $1.1 million during Q1 2025.
  • Moreover, its 5-year median value for Cash & Equivalents was $2.0 million (2023), whereas its average is $2.5 million.
  • Per our database at Business Quant, BioNexus Gene Lab's Cash & Equivalents skyrocketed by 32036.61% in 2023 and then tumbled by 8129.0% in 2025.
  • Over the past 5 years, BioNexus Gene Lab's Cash & Equivalents (Quarter) stood at $2.1 million in 2021, then dropped by 0.24% to $2.1 million in 2022, then skyrocketed by 113.21% to $4.5 million in 2023, then plummeted by 36.1% to $2.9 million in 2024, then plummeted by 52.99% to $1.4 million in 2025.
  • Its Cash & Equivalents stands at $1.4 million for Q3 2025, versus $1.5 million for Q2 2025 and $1.1 million for Q1 2025.